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ARTICLE
Pathogenic variants in glutamyl-tRNAGln
amidotransferase subunits cause a lethal
mitochondrial cardiomyopathy disorder
Marisa W. Friederich1, Sharita Timal2,3, Christopher A. Powell4, Cristina Dallabona5, Alina Kurolap6,7,
Sara Palacios-Zambrano et al.#
Mitochondrial protein synthesis requires charging mt-tRNAs with their cognate amino acids
by mitochondrial aminoacyl-tRNA synthetases, with the exception of glutaminyl mt-tRNA
(mt-tRNAGln). mt-tRNAGln is indirectly charged by a transamidation reaction involving the
GatCAB aminoacyl-tRNA amidotransferase complex. Defects involving the mitochondrial
protein synthesis machinery cause a broad spectrum of disorders, with often fatal outcome.
Here, we describe nine patients from ﬁve families with genetic defects in a GatCAB complex
subunit, including QRSL1, GATB, and GATC, each showing a lethal metabolic cardiomyopathy
syndrome. Functional studies reveal combined respiratory chain enzyme deﬁciencies and
mitochondrial dysfunction. Aminoacylation of mt-tRNAGln and mitochondrial protein trans-
lation are deﬁcient in patients’ ﬁbroblasts cultured in the absence of glutamine but restore in
high glutamine. Lentiviral rescue experiments and modeling in S. cerevisiae homologs conﬁrm
pathogenicity. Our study completes a decade of investigations on mitochondrial aminoacy-
lation disorders, starting with DARS2 and ending with the GatCAB complex.
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M itochondrial disorders are highly heterogeneous due totheir complex biochemistry and genetics. The oxidativephosphorylation system (OXPHOS) is essential for
proper ATP production and organism function. It consists of 98
proteins distributed across ﬁve multi-subunit complexes (I–V)
encoded by both the nuclear and mitochondrial genomes. The 13
mtDNA-encoded subunits belong to complexes I, III, IV, and V,
and all the subunits belonging to complex II are encoded by
nuclear DNA. The nuclear encoded mitochondrial genes are
transcribed in the nucleus, their mRNAs are translated in the
cytosol and proteins are imported to the mitochondria through a
complex import machinery. OXPHOS system biogenesis is
therefore the result of precise and coordinated cytosolic and
mitochondrial translational processes, the end result of which is
to obtain the appropriate stoichiometric levels of OXPHOS sub-
units to assemble into functional complexes. The mitochondrial
DNA-encoded subunits are transcribed and then translated on
the mitochondrial ribosomal machinery prior to assembly into
the complexes. Precise mRNA-to-protein translation by the
mitochondrial protein synthesis machinery1 is necessary for
OXPHOS assembly, and requires that each tRNA is paired with
the correct amino acid to allow that codon-anticodon pairing
results in proper protein formation2. In the mitochondria, this
process is mediated by the mitochondrial aminoacyl-tRNA syn-
thetases (ARS2s), which are encoded by nuclear genes. Of these,
17 ARS2 are unique to the mitochondria, while GARS (Glycyl-
tRNA synthetase) and KARS (Lysyl-tRNA synthetase), are
encoded by the same loci as the cytoplasmic enzymes, with the
mitochondrial isoforms being generated by alternative translation
initiation (GARS)3 or alternative splicing (KARS)4. By exception,
glutaminyl mt-tRNA (mt-tRNAGln) is aminoacylated by an
indirect pathway5, in which it is ﬁrst charged with glutamic acid
(Glu) by mitochondrial glutamyl-tRNA synthetase (EARS2), after
which the Glu-mt-tRNAGln is transamidated into Gln-mt-
tRNAGln, using free glutamine as an amide donor (Fig. 1a)5.
This latter conversion is performed by GatCAB, the glutamyl-
tRNAGln amidotransferase protein complex, that consists of three
subunits: GatA encoded by QRSL1, GatB encoded by GATB, and
GatC encoded by GATC5,6.
Over the past decade, pathogenic variants in all ARS2 genes
and in QRSL17,8 have been associated with a variety of metabolic
phenotypes9. In this report, we provide evidence of mitochondrial
function defects caused by GatCAB pathogenic variants, includ-
ing gene defects in GATB and GATC. Patients present with
metabolic cardiomyopathy and have defective Gln-mt-tRNAGln
acylation, resulting in reduced mitochondrial protein translation
with an inﬂuence of the amount of glutamine available. Thus, the
account of mitochondrial aminoacylation defects in human dis-
ease, that started with the discovery of pathogenic mutations in
DARS210 in 2007, is now completed by the discovery of defects in
GATB and GATC.
Results and Discussion
Clinical presentation. We studied ﬁve families (Fig. 1b–f) with
infants predominantly exhibiting severe cardiomyopathy and
fatal lactic acidosis, which raised suspicion of mitochondrial
disease. The onset of symptoms was either prenatal (families 1
and 3) or infantile at 2–5 months (families 2, 4, and 5), and no
child survived beyond 6.5 months. Anemia, which is a rare
symptom in mitochondrial disorders11–13, was frequently present,
ranging in severity from mild to severe prenatal anemia requiring
intrauterine transfusions. The bone marrow biopsy did not show
ringed sideroblasts in any of the subjects. Additional features
present in several subjects include liver dysfunction, mildly ele-
vated creatine kinase levels, and hydropic features including
pericardial effusion. Postmortem biopsies revealed cardiomyo-
cytes with massive mitochondrial proliferation, as observed on
electron microscopy and on histology represented by rarefactions
in the cytoplasm staining (Fig. 1g–l). Biochemical investigations
showed abnormalities of the mitochondrial respiratory chain
enzymes (Supplementary Table 1). The complete clinical pre-
sentations of the patients are summarized in Table 1, and the full
clinical reports are available in Supplementary Note 1. A similar
presentation of early lethal cardiomyopathy was noted in the few
previously reported QRSL1 cases7,8.
Genetics. Whole exome sequencing (WES) analysis in these
families uncovered rare pathogenic variants in the three genes
encoding the GatCAB complex subunits, in-line with autosomal
recessive inheritance (Fig. 1b–f, Supplementary Table 2 and
Supplementary Fig. 1). In family 1, compound heterozygous
variants were identiﬁed in GATB: paternal c.580_581del; p.
Ser194Trpfs*15 and maternal c.408T>G; p.Phe136Leu. In family
2, we identiﬁed compound heterozygous variants in QRSL1:
paternal c.555C>A; p.Tyr185* and maternal c.398G>T; p.
Gly133Val, which has been previously described7. In family 3,
WES revealed compound heterozygous variants in QRSL1:
paternal c.[587C>A;590G>A;596C>A]; p.[Thr196Asn;Arg197Lys;
Pro199His] and maternal c.[1279G>T;1280C>T]; p.Ala427Leu. In
families 4 and 5, which are reportedly not related but reside in
adjacent villages, we identiﬁed a homozygous missense variant in
GATC: c.233T>G; p.Met78Arg. Segregation analysis conﬁrmed
co-segregation among available affected and healthy siblings and
parents in all families. All missense variants were predicted to be
deleterious by the bioinformatics programs PolyPhen2 and
MutationTaster, and most by SIFT (Supplementary Table 2); only
Gly133Val was predicted as tolerated by SIFT, yet this variant has
been previously shown as functionally damaging7.
Due to their essential role in protein synthesis, residual enzyme
activity characterizes disorders of tRNA synthetases, and
complete loss-of-function is thought to be embryonically
lethal9,14,15. Therefore, a pathogenic variant in tRNA-charging
genes should be damaging enough to prevent normal respiratory
chain enzyme activity, whereas, mild enough to maintain residual
respiratory chain enzyme activity required for viability9,14. All
patients reported herein have at least one missense allele that may
account for residual GatCAB activity. In addition, we observed a
possible relation between clinical severity and the degree of amino
acid conservation, i.e., the most severely affected families 1 and 3
with prenatal onset and neonatal demise had a missense variant
involving highly conserved amino acids, whereas families 2, 4,
and 5 with infantile onset had missense variants that affected
moderately conserved amino acids (Supplementary Fig. 1). In
many biochemical genetic conditions, the phenotypic severity
relates to the amount of residual enzyme activity, which could be
due to the effect of missense mutations, or, more rarely, leaky
splicing defects, or penultimate 3’stop mutations. A leaky splice
site mutation in QRSL1 was previously reported8. In the patients
presented here, frameshift and null mutations are likely to result
in complete loss of protein expression. Thus, we postulate that the
phenotypic variability relates to the level of residual activity of
each missense mutation, with the severity of their functional
effect reﬂected in the amino acid conservation and the effect on
the protein structure and function in the modeling below, with
the most stringently conserved amino acids related to the earlier
presentation.
Molecular modeling of protein structure and function. In the
bacterial GatCAB complex, GatA and GatB possess the catalytic
amidase and kinase functions, respectively, while GatC serves as a
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Fig. 1 Pathogenic variants in GatCAB subunits lead to a lethal metabolic cardiomyopathy. aMitochondrial-tRNAGln is charged with glutamine in a two-step
reaction. b–f Pedigrees of the families with pathogenic variants in QRSL1, GATB, or GATC as identiﬁed in the patients. g–l Pathology of patients' heart
tissues. g–i Light microscopy on hematoxylin-eosin staining showed pericardial clearing in patients g P3A (GatA, magniﬁcation 100X), h P1A (GatB,
magniﬁcation 100X (scale bar 20 μm), and i P4A (GatC, magniﬁcation 100X). j, k Electron microscopy of the heart showed extensive mitochondrial
proliferation displacing the contractile elements in patients j P3A (GatA, magniﬁcation 2700X, insert magniﬁcation 27,000X) and k P4A (GatC,
magniﬁcation 2500X (scale bar 5 μm), insert magniﬁcation 12,000X (scale bar 2 μm). l SDHB immunostaining in patient P4A (GatC) showed massive
increase in mitochondria in the heart (magniﬁcation 100X)
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stabilizing linker between them16. To discern the effects that the
mutations have on the structure and function of this enzyme, the
variants identiﬁed in the patients were modeled in the human
GatCAB complex (Fig. 2a, b). In GatB, Phe136 mutated in P1A is
located in a hydrophobic region, in close proximity to the cata-
lytic residues of the amidotransferase site and to the GatA–GatB
interface (Fig. 2f). The Phe136Leu mutation preserves the
hydrophobic character of the region, but the reduced side chain
size could reposition residues forming this hydrophobic core with
potential long-range impact, and the absence of the phenyl-ring
could weaken the π–π interaction with GatB Phe82. Owing to
large-scale effects and the proximity of the affected residue to the
amidotransferase site, the Phe136Leu mutation can lead to
reduced catalytic activity.
In GatA, Gly133 mutated in P2A is located in a loop close to
the glutaminase center and is crucial for this region’s conforma-
tion by promoting a β-turn structure though backbone interac-
tion with Ser130, and in the absence of a sidechain allowing
greater ﬂexibility to the loop (Fig. 2c). The Gly133Ala mutation
introduces an aliphatic sidechain, which would contrapose these
contributions to the structure indirectly perturbing the con-
formation of its catalytic site. This predicted deleterious effect
explains the previously published pathogenicity7.
The residues Thr196, Arg197, and Pro199 mutated in P3A are
buried within GatA close to its glutaminase center, and their
mutations likely affect structure and function (Fig. 2d). Especially
critical is Thr196, which directly contacts Ser195, the catalytic
residue, and its side chain is surrounded by the backbone of
residues composing the β-sheet of GatA and by the side chain of
Leu233, to which its ramiﬁed aliphatic portion establishes
hydrophobic interactions. The alteration in Thr196Asn to a
bulkier asparagine could not only sterically perturb the β-sheet
structure, but also shift the position of the connecting catalytic
Ser195 affecting catalysis. Residue Arg197 is located in a polar
pocket where it interacts with carboxyl and carbonyl groups of
surrounding aspartate, asparagine, and glutamine residues.
Despite similar physicochemical properties of arginine and lysine,
the guanidinium group of arginine is able to establish more
simultaneous interactions than the ε-amino group of lysine,
providing more stabilizing interactions; hence Arg197Lys may
compromise the stability of its vicinity. The non-polar ring of
Pro199 is exposed to the backbone of catalytic residues Ser195
and Ser171 responsible for glutamine intermediate formation and
charge relay. The Pro199His mutation may impact the helix
structure, and the larger size of the histidine side chain may cause
steric disturbances, and may further establish new interactions
with the backbone of neighboring residues of the glutaminase
center, which displacement may impact catalysis.
Ala427 mutated in P3A is exposed on the surface of GatA,
away from surfaces of interaction with the other subunits of the
GatCAB complex, and in the Ala427Leu mutation both amino
acids are hydrophobic, with only an increased side chain size with
limited steric effect since this residue is located in a solvent-
exposed surface, thus predicting limited impact likely with some
residual activity present (Fig. 2e).
In GatC, Met78 mutated in families 4 and 5 is located at the
interface of the GatC subunit with GatA where this electron-rich
residue interacts with the aliphatic segment of two positively
charged arginine residues (Fig. 2g). The Met78Arg mutation
disrupts these interactions by electrostatic repulsion compromis-
ing the interaction between GatC and GatA.
GatCAB complex levels. The steady state protein levels of the
GatCAB subunits are variably affected by the mutations as
determined through western blot analysis. Fibroblasts from sub-
ject P1A with mutations in GATB, showed strongly reduced levels
of the GatB protein in comparison to controls (Fig. 3a). The
GatCAB holocomplex is approximately 120 kDa in control
ﬁbroblasts by blue native polyacrylamide gel electrophoresis (BN-
PAGE) analysis, compatible with a complex consisting of one
copy of each component, but in affected subjects’ ﬁbroblasts this
complex was not detected (Fig. 3b). In subject P3A with muta-
tions in QRSL1, there is no effect on protein expression of the
GatA protein between affected subject and controls in heart and
skeletal muscle (Fig. 3c), yet the holocomplex at 120 kDa was
consistently absent in the affected subject in muscle and heart
tissues, but normal in cultured skin ﬁbroblasts, which is com-
patible with the normal respiratory chain enzymes in these cells
(Fig. 3d). In subject P4B with mutations in GATC, the steady state
level of GatC in ﬁbroblasts was decreased to 20% of controls
(Fig. 3e), and the GatA and GatB protein levels were equally
Table 1 Symptoms of patients with deﬁcient GatCAB complex
P1A P1B P2A P3A P4A P4B P4C P5A P5B
Gender M F M F M M F M F
Age at onset Prenatal
34 weeks
Prenatal
30 weeks
3 months Prenatal
13 weeks
3 months 2 months 3 months 5.5 months 3 months
Age at death 2 days 1 day 3 months 1 day 3 months 2 months 3.5 months 6.5 months 6.5 months
Affected gene GATB GATB QRSL1 QRSL1 GATC GATC GATC GATC GATC
Prenatal Frequency
Hydrops 3/9 √ √ – √ – – – – –
IUGR 2/9 √ √ – – – – – – –
Postnatal
Prematurity 2/9 √ – – √ – – – – –
Cardiomyopathy 9/9 √ √ √ √ √ √ √ √ √
Lactic acidosis 9/9 √ √ √ √ √ √ √ √ √
Anemia 7/7 √ √ √ √ √ NA NA √ √
Hepatic dysfunction 5/9 – – √ – √ √ √ √ –
Elevated CK 5/9 – – – √ √ √ √ √ –
Hypoglycemia 2/9 – √ √ – – – – – –
Hearing loss 1/1 NA NA √ NA NA NA NA NA NA
Low cortisol 1/2 – NA NA √ NA NA NA NA NA
Frequency of symptoms identiﬁed in the patients with defects in the GatCAB complex
√ symptom present, - symptom not present, CK creatine kinase, IUGR intrauterine growth restriction, NA data not available
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substantially decreased (Fig. 3e), probably due to the instability of
the individual subunits when they are not incorporated in the
GatCAB trimer. To exclude a genetic regulatory effect on the
expression of QRSL1, GATB, or GATC provoked by the reduction
of the GatCAB subunits in patient ﬁbroblasts, we analyzed their
mRNA levels in exponentially growing ﬁbroblasts from patients
P3A and P4B and found no signiﬁcant changes in the tran-
scriptional rate of the three genes compared to controls (Sup-
plementary Fig. 2).
A defect in mitochondrial translation. Analysis of the mito-
chondrial respiratory chain enzymes in all patients showed a
combined deﬁciency with decreased activities of complexes I and
IV, and low or borderline-low activity of complex III, that varied
between the different tissues tested (Supplementary Table 1). In
contrast to the ﬁbroblasts of the GatA and GatC patients, clear
respiratory chain enzyme deﬁciencies were observed in the
ﬁbroblasts of the GatB patients. BN-PAGE with in-gel activity
staining of heart muscle, skeletal muscle, and liver samples from
patient P3A (GatA) conﬁrmed reduced activities of complexes I
and IV with the presence of pathogenic lower molecular weight
bands of complex V (Fig. 4a). In addition, observed subassemblies
of complex I were present in heart and muscle (Fig. 4b), and were
more prominent in ﬁbroblasts when grown in medium without
glutamine (Fig. 4c). Fibroblasts from patient P3A showed normal
respiration compared to controls in culture medium containing
glutamine, but after withdrawal of glutamine for three or six days,
the CCCP-uncoupled maximum rate, and the calculated complex
I and complex IV activities were signiﬁcantly decreased (Fig. 4d).
Taken together, these ﬁndings are consistent with a defect in
mitochondrial translation with marked tissue speciﬁc differences
most pronounced in heart, less in skeletal muscle, and near absent
in ﬁbroblasts, but exaggerated upon glutamine reduction.
Given the extensive tissue differences observed for the effects of
the GatCAB complex genes in our subjects, the question arose
whether another protein such as QARS could contribute to the
aminoacylation of mt-tRNAGln in certain tissues such as
ﬁbroblasts. Certain previous publications and databases referred
to cytoplasmic QARS as an ARS that operates in both
mitochondrial and cytoplasmic compartments.17–21 To
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experimentally verify if QARS would localize in human
mitochondria, we expressed QARS in fusion with green
ﬂuorescence protein (QARS-GFP) in human cells and studied
its cellular localization using confocal microscopy. We did not
detect any apparent co-localization of QARS-GFP with the
mitochondrial protein TOM20 (Supplementary Fig. 3a, b).
Furthermore, cellular fractionation experiments of human cells
did not show any substantial enrichment of the endogenous
QARS within the mitochondrial fraction (Supplementary Fig. 3c).
The very low amount of QARS fractionating with mitochondria
was sensitive to proteinase K treatment, conﬁrming that that
there is no detectable QARS within human mitochondria
(Supplementary Fig. 3c). Therefore, mitochondria are exclusively
dependent on the GatCAB complex for appropriate charging of
mt-tRNAGln with glutamine. While aminoacylation of mt-
tRNAGln appears to show only minor changes in comparison to
controls when patient cells are grown under standard conditions
with high concentrations of the GatCAB substrate glutamine in
the culture medium (Fig. 3f), the aminoacylation in patient cells is
strongly impaired in minimal essential culture medium that lacks
the non-essential amino acid glutamine (Fig. 3g).
The impact of the impairment in mt-tRNAGln charging on the
mitochondrial protein synthesis capacity in the ﬁbroblasts from
subjects P3A and P4B was evaluated. Pulse labeling of
mitochondrial proteins with [35S]-methionine in the presence
of emetine, a cytoplasmic protein synthesis inhibitor, revealed a
strong and generalized mtDNA-encoded protein synthesis defect
after a 90-min pulse in P4B (GATC) and in P3A (QRSL1)
patients’ ﬁbroblasts (Fig. 5a). It is remarkable that this
impairment of mitochondrial DNA-encoded protein synthesis
correlates with no apparent changes in the steady state levels of
representative OXPHOS proteins reﬂecting the assembled
mitochondrial complexes (Fig. 5b). The nuclear DNA-encoded
mitochondrial proteins NDUFB8 and UQCRC2 are unstable
when not incorporated into their corresponding complexes, thus
they are an accurate reﬂection of the levels of integral complexes I
and III containing mtDNA-encoded proteins as previously
described22–26. The possibility that the decrease of NDUFB8
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and UQCRC2 levels is the result of a retrograde response seems
improbable. RT-qPCR experiments showed no decrease in their
mRNA levels in the mutant ﬁbroblasts (Supplementary Fig. 4).
Rather, NDUFB8 and COXVA mRNAs levels increase, compa-
tible with a decrease in NDUFB8 protein levels as a consequence
of its instability when it is not incorporated into its respective
complex; in contrast, the mRNA levels of COXVA, which is part
of a stable F1 subcomplex V, are unchanged. Further, the majority
of retrograde responses to mitochondrial function defects, when
they occur, results in the increase of compensatory protein levels
and enzyme activities. Thus, the absence of changes in the steady
state levels of COXII, NDUFB8, and UQCRC2 together with the
reduced de novo synthesis of mitochondrial DNA-encoded
proteins suggest a possible increase in the stability of the
respiratory chain subunits in mutant cells. This was conﬁrmed
by incubation of P4B ﬁbroblasts in the presence of chloramphe-
nicol to arrest mitochondrial protein biosynthesis and harvesting
these cells and analyzing them at different times for up to 120 h
(Fig. 5c). The combined effect of an increase in stability as
observed, together with residual GatCAB activity in ﬁbroblasts,
could explain the lack of substantive changes in steady state levels
of complexes I, III, and IV.
We next analyzed the ability of the P4B (GATC) ﬁbroblasts to
recover de novo synthesis after arresting mtRNA translation
using chloramphenicol treatment and release. No changes were
observed on the mitochondrial translation, suggesting an
accumulation of precursors during chloramphenicol treatment
and their higher availability when released (Fig. 5d). These
precursors would include mt-tRNAGln charged with glutamine,
allowing for translation to occur at a normal (or close to normal)
rate for a few hours (lanes 1, 2, 3; Fig. 5e). However, during
continued translation, the rate of charging mt-tRNAGln with
glutamine cannot keep up with the demand, and translation
efﬁciency decreases (lanes 4, 5, 6; Fig. 5e) compared untreated
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ﬁbroblasts (lanes 7, 8, 9; Fig. 5e). These data demonstrate that the
biochemical phenotype becomes more prominent under condi-
tions that place the charging of mt-tRNAGln under stress.
Lentiviral rescue experiment. To conﬁrm that the GATB gene
defect in family 1 was responsible for the respiratory chain
enzyme deﬁciencies in the infant’s ﬁbroblasts, a lentiviral trans-
duction experiment was performed with wild-type GATB with a
C-terminal V5-tag attached to it. The expression levels of GatB
protein obtained after transduction with the GATB transgene
were very similar to those of the endogenous GatB protein in
control cells (Fig. 6a). The expression of the transgene in the
affected subject’s ﬁbroblasts resulted in a complete rescue of the
respiratory chain enzyme deﬁciencies, indicating that indeed the
GATB gene variants in this subject caused the enzyme deﬁciencies
(Fig. 6b). Using the V5-tag, the expression of the transgene could
be monitored at the subcellular level. A transient transfection
experiment in U2OS cells revealed that the location of the V5-
GatB protein was strictly mitochondrial, conﬁrming correct cel-
lular localization and is compatible with its function as part of the
mitochondrial GatCAB complex (Fig. 6c).
Mutation expression in Saccharomyces cerevisiae. In addition,
to validate the pathogenicity of the QRSL1 (GATA) and GATB
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loading control. Western blots show protein levels of NDUFB8 (complex I), UQCRC2 (complex III), ATP5A1 (complex V), COXI and COX II (complex IV)
and SDHB (complex II) and β-actin (loading control) (b, c, d). NDUFB8 and UQCRC2 are labile if not incorporated into fully assembled complexes I and III,
respectively, thus being an indirect indicator of the levels of mtDNA-encoded proteins within OXPHOS complexes. SDHB and ATP5A1 levels should not
change (as it is shown) since both are encoded in the nucleus. In the absence of the complex V mtDNA-encoded proteins, ATP5A1 remains assembled and
stable in the F1 subcomplex. a Decrease in newly synthesized peptides in GATA and GATC patient ﬁbroblasts compared to control as determined by pulse
labeling. Not all of the 13 mtDNA-encoded proteins can be seen. b Western Blot analysis showing that steady state levels of respiratory chain enzyme
subunits are not reduced in patients P3A (QRSL1) and P4B (GATC) ﬁbroblasts. Levels of NDUFB8 and UQCRC2 reﬂect the levels of mtDNA encoded
proteins of complexes I and III, respectively. c Western blot analysis showing increased stability for NDUFB8, COXI, and COXII in patient P4B (GATC)
ﬁbroblasts after blocking mitochondrial protein synthesis with chloramphenicol (Cm) from 0 to 120 h. d Recovery of OXPHOS complexes containing
mtDNA-encoded proteins in ﬁbroblasts of patient P4B after release of mitochondrial protein synthesis blockade with chloramphenicol. e [35S]-methionine
labeling of mitochondrial protein synthesis after a transient block with Cm. Chloramphenicol completely inhibits mitochondrial protein synthesis (right
lane). Densitometric analysis was performed. Coomassie stained gels were used for protein loading normalization, images were analyzed with ImageJ,
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for 2–3 experiments were pooled
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mutations identiﬁed in the affected subjects we used the yeast S.
cerevisiae as a model system taking advantage of the presence of
the orthologous genes, HER2 and PET112, respectively. GATC
was not included in this experiment as yeast lacks an ortholog for
this gene.
As shown by GATA/Her2 protein alignment (Fig. 7a) the
human residues, Arg197 and Pro199, are invariant from human
to yeast, corresponding to Arg156 and Pro158 in yeast,
respectively. On the contrary, the human amino acid residues
Gly133, Thr196, and Ala427 are not conserved in yeast,
corresponding in yeast to Ser109, Val155, and Pro397, respec-
tively. For the analysis of pathogenicity of these three non-
conserved residues it was necessary to create both the so called
humanized version and the potentially pathological allele to
compare their effect on mitochondrial function. The humanized
version was created by replacing the yeast amino acid with the
corresponding amino acid present in the wild-type human allele,
as previously described27 (Fig. 7b). In order to reveal a possible
respiratory growth defect, serial dilutions of the strains were
spotted on SC medium supplemented with either glucose or
ethanol at 28 °C. The oxidative growth of the strains expressing
the humanized versions her2hS109G and her2hV155T was similar to
that of the wild type (Fig. 7c). The strains expressing the mutant
alleles her2S109V (subject P2A) and her2V155N-R156K-P158H (subject
P3A, paternal allele) show a severely reduced or totally absent
oxidative growth. On the contrary, the strain with the humanized
allele her2hP397A shows a slight reduction of growth with respect
to the strain with the wild-type version, whereas the strain with
mutant version her2P397L (subject P3A, maternal allele) shows a
severe oxidative defective phenotype. Further, the oxygen
consumption rate was reduced for all mutants, although to a
different extent (Fig. 7e). In particular, parallelizing the growth
defect, the mutant her2V155N-R156K-P158H behaved as the null
mutant, whereas the mutants her2S109V and her2P397L showed a
reduction of the respiratory rate with respect to its humanized
version of about 70% and 35% respectively. Overall, the data
obtained indicate a pathogenic nature for each of the analyzed
variants.
To validate the pathogenicity of the new missense mutation p.
Phe136Leu in the GATB gene observed in family 1, we introduced
the change equivalent to the human mutation into the yeast
PET112 wild-type gene cloned in a centromeric monocopy vector.
As shown by protein alignment (Fig. 7a), the human residue
Phe136 is invariant in yeast corresponding to Phe103. Oxidative
growth and oxygen consumption of the mutant strain
pet112F103L, measured in the same experimental condition as
for the her2 mutants, did not reveal any defect (Supplementary
Fig. 5). We then compared wild-type and mutant strain in a more
stressing environmental condition of high temperature (37 °C)
and absence of the amide donor glutamine. When grown at 37 °C
the mutant displayed a 20% reduction of respiratory activity
(Supplementary Fig. 6), whereas at same temperature in the
absence of glutamine the mutant showed a defective oxidative
growth (Fig. 7d) and a severe (70%) reduction of oxygen
consumption (Fig. 7f). These data support the pathogenic role of
the Phe136Leu mutation.
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In conclusion, pathogenic variants in each of the subunits of
the GatCAB complex impair the function of this critical enzyme
complex. Decreased GatCAB activity reduces the amounts of
glutamine-charged mt-tRNAGln and disturbs mitochondrial
translation for nearly all mtDNA-encoded the OXPHOS subunits.
The impact was most evident in highly respiring tissues like the
heart, and less so in ﬁbroblasts, a mostly glycolytic tissue with low
respiratory needs. Reduced mitochondrial translation and the
ensuing effect on respiratory functions correspond to the clinical
phenotype, consisting of cardiomyopathy and lactic acidosis with
early lethality, regardless of the subunit involved. It remains to be
seen if the increased activity in higher cognate amino acid
concentrations may guide potential future therapeutic opportu-
nities in disorders of translational defects.
Methods
Participants. The study was performed in accordance with the ethical standards of
the Declaration of Helsinki. All studies were done in agreement with the rules of
the local medical ethics committees. Studies on family 3 were done following IRB
approved protocols 07-0386 and 16-0146 approved by the Colorado Multiple
Institutional Review Board (COMIRB) at the University of Colorado, and in
families 4 and 5 following protocol 0038-14-RMB approved by the Helsinki
Committee at Rambam Health Care Campus. Written consent was obtained from
all participants that provided samples. Studies on families 1 and 2 were exempt
from formal IRB/Ethics board review, as per the local rules at the University of
Nijmegen and in Adelaide.
Exome sequencing. WES was done using previously described methodologies and
ﬁltering pipelines as singleton for families 1 and 228, and trio-based for families 329
and 430. In brief, exome enrichment was done using Agilent SureSelect Human All
Exon 50 Mb Kit (Agilent Technologies, Santa Clara, CA) for families 1 and 2,
Agilent Sure Select All Exon v4 for family 3, and the Nextera Rapid Capture
Enrichment kit (Illumina) for family 4, followed by sequencing on a
HiSeq2000 sequencer (Illumina, San Diego, CA) for families 1, 2, and 4, and the
Illumina HiSeq2500 for family 3. All reads were aligned to the reference genome
assembly GRCh37/hg19. Following quality assurance of the reads, the bioinfor-
matics analyses focused on protein-altering variants (missense, nonsense, frame-
shift, and splice-site). Variants were ﬁltered based on frequency in healthy
population databases (dbSNP31, 1000Genomes32, Exome Aggregation Consortium
- ExAc33, and NHLBI GO Exome-sequencing Project (evs.gs.washington.edu/EVS),
and population-speciﬁc databases, such as the Greater Middle-East Variome
Project34 and the Genome of the Netherlands - GoNL35) and in-house databases
(<0.5%), and variants were examined using various inheritance models, including
dominant (de novo variants), and recessive (compound heterozygous, homo-
zygous, and X-linked hemizygous variants) models. Candidate variants in QRSL1,
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GATB, and GATC were conﬁrmed by Sanger sequencing. For family 5, Sanger
sequencing was performed for presence of the speciﬁc GATC variant. The following
transcripts are used in the description of the candidate variants: QRSL1
ENSG00000369046 (NM_018292); GATB ENST00000263985 (NM_004564),
GATC ENST00000551765.5 (NM_176818). All missense variants were examined in
silico for pathogenicity using the programs PolyPhen 2 (v2.2humvar)36, SIFT
(JCVI-SIFT v.1.03)37, and MutationTaster38.
Respiratory chain enzyme activities and assembly analysis. Fibroblasts were
collected from patient P1A at autopsy and from patient P1B from a post mortem
skin biopsy. For patient P3A, a full autopsy was performed within one hour after
death with heart, liver, and skeletal muscle tissues collected, and a ﬁbroblast culture
derived from a skin biopsy. For patients P4A, and P5A, respiratory chain enzyme
activities were done on muscle biopsy, and for patient P4B on ﬁbroblasts derived
from a skin biopsy. Fibroblasts were routinely cultured in minimum essential
medium (MEM)-α with 2 mM glutamine and deoxyribonucleotides (SH3026501
Hyclone) with 10% bovine serum product. For experiments with limited glutamine,
ﬁbroblasts were cultured in MEM (M2279 Sigma-Aldrich) with 10% bovine serum
product for the stated duration.
The respiratory chain enzyme activities were measured spectrophotometrically
in ﬁbroblasts of patients P1A-B and in skeletal muscle, and liver of patient P2A, in
Nijmegen as previously described39; in muscle, liver, heart, and skin ﬁbroblasts of
patient P3A, and ﬁbroblasts of P4B in Colorado, as previously described40,41; and
in muscle biopsies of patients P4A and P5A in Israel, as previously described42.
Additionally, isolated mitochondrial membrane fractions of muscle, heart, liver,
and ﬁbroblast samples of P3B, and ﬁbroblasts of P4B were analyzed by BN-PAGE
with in-gel activity staining40,41,43, and the assembly of complex I in the P3B
patient was assessed by western blotting following non-denaturing BN-PAGE of
isolated mitochondrial membrane fractions of muscle, heart and ﬁbroblasts using
an antibody for NDUFS2, a component of the earliest complex I assembly
intermediate29.
Protein analysis by western blot. Western blot analysis was performed on
mitochondria isolated by differential centrifugation from the patients' skeletal
muscle, heart muscle, liver, and cultured skin ﬁbroblasts, and detected using the
appropriate HRP-conjugated secondary antibody followed by enhanced chemilu-
minescence in families 1–3, using antibodies for GatA, citrate synthase, GatB,
GatC, green ﬂuorescent protein, and for V5. The sources of all antibodies used in
this study are listed in Supplementary Table 3.
Fibroblast pellets were incubated in RIPA buffer containing protease inhibitors
followed by centrifugation, separation of proteins on SDS-PAGE gels,
immunoblotted, and detected with the primary antibodies with quantitative
analysis using ImageJ software using antibodies against MT-COXI, GatA, GatB,
GatC, VDAC1, total human respiratory chain western blot antibody cocktail, which
contains antibodies against complex I subunit NDUFB8, complex II subunit
30kDa, complex III subunit core 2 (UQCRC2), complex IV subunit II (COX II),
and ATP synthase subunit-α (ATP5A1). The assembly of the glutamyl-tRNA (Gln)
amidotransferase complex was analyzed on a native gel followed by western
blotting using an anti-GatB antibody. This analysis also provided an estimation
of the size of the complex, and a possible super complex. All the uncropped
western blots with molecular weight indicated are included in Supplementary
Figures 7–16.
mRNA analysis. Levels of mRNAs of the different GatCAB subunits were analyzed
by RT-qPCR. These assays were carried out on RNA extracted from ﬁbroblasts
using HPRT levels for normalization, and two primer pairs were used for each PCR
target (primers are available upon request).
Respirometry assays. Cellular oxygen consumption was measured by high-
resolution respirometry on an Oroboros Oxygraph2k, using a SUIT protocol29 for
patients P3A and P4B, with experiments done in ﬁbroblasts grown in glutamine-
containing MEM-α and in minimal MEM tissue culture media.
Aminoacylation assay. The impact of candidate variants in the GatCAB complex
on the aminoacylation of mt-tRNAGln was analyzed using RNA isolated from
ﬁbroblasts grown in standard tissue culture medium supplemented with Glutamax,
and/or in ﬁbroblasts grown in MEM without glutamine44. RNA was extracted from
subconﬂuent ﬁbroblasts using Trizol (Life Technologies), and the ﬁnal RNA pellet
was dissolved in 10 mM sodium acetate, pH 5.0 at 4 °C. For the deacylated (dAc)
control, the pellet was resuspended in 200 mM Tris-HCl at pH 9.5 and incubated at
75 °C for 5 min, followed by RNA precipitation and resuspension in 10 mM
sodium acetate buffer pH 5. Next, 5 µg of RNA was separated on a 6.5% poly-
acrylamide gel (19:1 acrylamide:bisacrylamide) containing 8M urea in 0.1 M
sodium acetate pH 5.0 at 4 °C and blotted to Hybond N+ membranes (Amersham
RPN303B). Following UV-crosslinking, the blots were washed in hybridization
buffer of 7% SDS, 0.25 M sodium phosphate pH 7.6 for 1 h at 65 °C. The mem-
brane was subsequently incubated overnight at 65 °C in hybridization solution with
32P-labeled antisense RNA probes, generated by in vitro transcription by T7 RNA
polymerase in the presence of 32P-labeled alpha-UTP, using linearized templates.
After hybridization, the blots were washed six times with 1x SSC for 15 min at 65 °
C. Bound probes were detected by phosphor imaging on an Amersham Typhoon
Scanner.
Pulse labeling of mitochondrial translation products. In vivo labeling of mito-
chondrial translation products was carried out as previously described6. Expo-
nentially growing 2.5x105 ﬁbroblasts were labeled for 90 min in methionine and
cysteine-free DMEM containing 200 μCi ml−1 of [S35]-methionine (Perkin Elmer)
and 100 μg ml−1 of the cytoplasmic protein synthesis inhibitor emetine. Cells were
harvested and total cellular protein was extracted from which 50 μg were loaded on
17.5% protein denaturing gels. After electrophoresis, gels were ﬁxed, incubated in
Amplify Fluorographic Reagent (GE Healthcare, ref. NAMP100) for 20 min and
dried. The labeled mitochondrial translation products were detected by direct
autoradiography.
Depletion and recovery of mitochondrial proteins. In order to analyze the
recovery kinetics of respiratory chain proteins after depletion, mtDNA-encoded
peptides were eliminated by treatment with 50 μg.ml−1 of the mitochondrial
translation inhibitor chloramphenicol for six days. The depletion of mtDNA-
encoded respiratory chain subunits impairs the assembly of respiratory chain
complexes I, III, IV, and V, which results in a depletion of the nuclear encoded
respiratory chain proteins identiﬁed in the human western blot antibody cocktail
described above. To analyze the recovery of complex I, III, and IV subunits,
chloramphenicol containing media was removed, cells were washed twice with
PBS, and incubated with chloramphenicol-free media. Cells were then collected at
0, 10, 16, 24, and 48 h after chloramphenicol removing, and analyzed by western
blot. In this experiment, the recovery of complex I NDUFB8, Complex III subunit
Core 2 and complex IV COX II is seen. Complex II, which is nuclear encoded, acts
as a control. Since the complex V subunit alpha belongs to F1-ATP synthase, which
assembles in the absence of mitochondrial subunits, it is not depleted by chlor-
amphenicol treatment45. To examine the recovery of mitochondrial protein
synthesis after chloramphenicol treatment, stressed by absence of cytoplasmic
protein translation, cells were washed and transferred to [S35]-methionine and
emetine-containing medium, and processed for autoradiography above.
Transfection experiments. A full-length cDNA (NM_004564.2) with or without a
stop codon was cloned into a pDONR201 vector, and recombined with pLenti6.2⁄
V5-DEST Gateway Vector, using the Gateway LR Clonase II enzyme mix (Invi-
trogen), and resulting in a lentiviral expression construct for V5-tagged GatB.
HEK293FT cells were transfected to produce lentivirus according to the manu-
facturer’s protocol (Invitrogen). The culture medium containing lentiviral particles
was harvested after 72 h, and was added to the patient and healthy control ﬁbro-
blasts. The next day, the virus was removed, and the medium was refreshed. After
48 h, 2.5 μg.ml−1 blasticidin was added to the medium to select for the transfected
cells, and after 14 days culture on selection medium, the blasticidin-resistant cells
were used for analysis. As a control, ﬁbroblasts were transduced with a GFP-V5
lentivirus. Expression of the transgenes was checked by western blot analysis using
anti-GFP and anti-V5 antibodies, and respiratory chain and citrate synthase
enzyme activities were measured. To examine the subcellular localization, the
pLenti6.2 plasmid with GatB-V5 was transfected to U2OS cells, and after 48 h
incubation, cells were stained using an anti-V5 and anti-HSP60 antibody, and
detected by confocal microscopy.
QARS cellular localization experiments. A human cDNA for QARS was obtained
from Source Bioscience (IMAGE ID 2821788), and following sequence veriﬁcation,
the cDNA was ampliﬁed by PCR and cloned into the pmaxGFP plasmid (Lonza)
in-frame with the GFP open reading frame using Gibson Assembly Master Mix
(New England Biolabs). In order to generate a positive control for mitochondrially
localized GFP, a mitochondrial targeting sequence coding for the ﬁrst 49 amino
acids from subunit F1β of human mitochondrial ATP synthase was also cloned
into pmaxGFP. The resulting plasmid DNA was transiently transfected into HeLa
cells grown to 50–60% conﬂuence in DMEM, containing 4.5 g l−1 glucose, 110 mg l
−1 sodium pyruvate, and supplemented with 10% FBS, 100 U.ml−1 penicillin and
100 μg.ml−1 streptomycin using Lipofectamine 2000 (Thermo Fisher Scientiﬁc),
according the manufacturer’s instructions. Transfected cells were ﬁxed, permea-
bilized, and immunostained with anti-TOM20 primary antibody and Goat Anti
Rabbit Alexa Fluor 594 secondary antibody46. To delineate the cell border, the cells
were additionally stained with CellTracker Blue CMAC Dye (Thermo Fisher Sci-
entiﬁc), according to manufacturer’s instructions and with DAPI to stain the
nucleus. Images were acquired using an A1R-Si Nikon N-SIM confocal micro-
scope. In order to further localize the endogenous QARS protein, cell fractionation
was performed47, and the QARS protein was detected by western blotting with
NDUFB8 and GAPDH as controls.
Yeast strains, plasmids, and media. The W303-1B genotype (obtained from
ATCC, catalog # 201238) is Matα ade2-1 leu2-3, 112 ura3-1 trp1-1 his3-11, 15
can1-100. All experiments except transformation were performed in synthetic
complete (SC) media (0.69% YNB without amino acids powder, ForMedium)
supplemented with 1 gr l−1 dropout mix48 without amino acids or bases necessary
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06250-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4065 | DOI: 10.1038/s41467-018-06250-w |www.nature.com/naturecommunications 11
to keep plasmids (i.e., uracil for pFL38 and tryptophan for the pFL39). Media were
supplemented with various carbon sources at 2% (w/v) (Carlo Erba Reagents), in
liquid phase or after solidiﬁcation with 20 g l−1 agar (ForMedium). Transformation
was performed after growth in YPAD medium (1% Yeast extract, 2% Peptone,
40 mg l−1 adenine base and 2% glucose)49. HER2 and PET112 were cloned under
their natural promoters by PCR-ampliﬁcation and inserted into the pFL38 vector50.
The pFL38-HER2 or pFL38-PET112 plasmid was introduced into the W303-1B
strain through the Li-Ac method51 and disruption of the genomic HER2 or PET112
gene was performed in this strain, since the deletion leads to mitochondrial DNA
loss51,52. The disruption was performed through one-step gene disruption by PCR-
ampliﬁcation of KanMX4 cassette53 from the BY4742 deleted strain using appro-
priate primers and transformation of the former strain; thus obtaining W303-
1Bher2Δ/pFL38-HER2 and W303-1Bpet112Δ/pFL38-PET112. HER2 and PET112
fragments were subcloned from pFL38 to pFL3950. HER2 and PET112 were
mutagenized by PCR overlap technique54 with appropriate primers to obtain the
humanized and mutant alleles, and subsequently they were cloned into the pFL39
vector. W303-1Bher2Δ/pFL38-HER2 was transformed with the pFL39 vector car-
rying the wild-type (HER2), or the humanized (her2hS109G or her2hV155T or
her2hP397A), or the mutant (her2S109V or her2V155N-R156K-P158H or her2P397L)
alleles, or with the empty vector as control, and then pFL38-HER2 was lost through
plasmid-shufﬂing. W303-1Bpet112Δ/pFL38-PET112 was transformed with pFL39-
PET112, pFL39-pet112F103L or the empty vector pFL39, and then pFL38-PET112
was lost through plasmid-shufﬂing. To evaluate mitochondrial respiratory activity
in yeast, the oxygen consumption rate was measured at 30 °C from yeast cell
suspensions cultured for 18 h at 28 °C or for 16 h at 37 °C in SC medium sup-
plemented with 0.6% glucose until exhaustion using a Clark-type oxygen electrode
(Oxygraph System Hansatech Instruments England) with 1 ml of air-saturated
respiration buffer (0.1 M phthalate–KOH, pH 5.0), 0.5% glucose.
Structural modeling of the human GatCAB complex. Amino acid sequences of
the GatC (O43716), GatA (Q9H0R6), and GatB (O75879) subunits were retrieved
from UniProt55 and parsed through SWISS-MODEL56 to search for modeling
templates. Templates were chosen considering coverage and identity: GatC was
modelled to the structure of the corresponding subunit in the Staphylococcus
aureus complex (PDB 2G5H)16; GatA was modelled using the subunit of Aquifex
aeolicus (PDB 3H0M)57; GatB was modelled using the high-resolution structure
from Staphylococcus aureus (PDB 3IP4)58. Finally, all models were aligned to the
bacterial GatCAB complex from Thermotoga maritima in the glutamylation state
(PDB 3AL0)59 using PyMOL60. The human GatCAB model was manually
inspected for clashes. The magnesium ion coordinated to the amidotransferase
centre was present in the structure of GatB from Thermotoga maritima, while ADP
and the magnesium ion coordinated by its phosphate groups were obtained
by aligning the structure of GatB from Aquifex aeolicus (PDB 3H0R)57 to the
corresponding modelled subunit. Residues relevant for the catalytic activity
at the amidotransferase site were mapped from the Saccharomyces cerevisiae
GatFAB complex.61 Structure visualisation and mapping of residues were per-
formed using PyMOL60.
Statistics. As needed, comparison between two groups was done by two sided
Student t-test paired or unpaired as indicated,with calculations done in either Excel
(Microsoft) or SPSS 24 (IBM).
Data availability
The molecular data are deposited in the ClinVar database (www.ncbi.nlm.nih.gov/
clinvar/), with accession numbers listed in Supplementary Table 4. All other data sup-
porting the ﬁndings of this study are available within the paper and the Supplementary
information. Quantitative data associated with Figs. 4, 6, and 7 are available upon
request.
Received: 9 February 2018 Accepted: 23 August 2018
References
1. Hällberg, B. M. & Larsson, N.-G. Making proteins in the powerhouse. Cell
Metab. 20, 226–240 (2014).
2. Mai, N., Chrzanowska-Lightowlers, Z. M. & Lightowlers, R. N. The process of
mammalian mitochondrial protein synthesis. Cell Tissue Res. 367, 5–20
(2016).
3. Chihara, T., Luginbuhl, D. & Luo, L. Cytoplasmic and mitochondrial protein
translation in axonal and dendritic terminal arborization. Nat. Neurosci. 10,
828–837 (2007).
4. Tolkunova, E., Park, H., Xia, J., King, M. P. & Davidson, E. The human lysyl-
tRNA synthetase gene encodes both the cytoplasmic and mitochondrial
enzymes by means of an unusual alternative splicing of the primary transcript.
J. Biol. Chem. 275, 35063–35069 (2000).
5. Nagao, A., Suzuki, T., Katoh, T., Sakaguchi, Y. & Suzuki, T. Biogenesis of
glutaminyl-mt tRNAGln in human mitochondria. Proc. Natl Acad. Sci. USA
106, 16209–16214 (2009).
6. Echevarria, L. et al. Glutamyl-tRNAGln amidotransferase is essential for
mammalian mitochondrial translation in vivo. Biochem J. 460, 91–101 (2014).
7. Kohda, M. et al. A comprehensive genomic analysis reveals the genetic
landscape of mitochondrial respiratory chain complex deﬁciencies. PLoS
Genet. 12, e1005679 (2016).
8. Kamps, R. et al. Genetic defects in mtDNA-encoded protein translation cause
pediatric, mitochondrial cardiomyopathy with early-onset brain disease. Eur.
J. Hum. Genet. 26, 537–551 (2018).
9. Sissler, M., Gonzalez-Serrano, L. E. & Westhof, E. Recent advances in
mitochondrial aminoacyl-tRNA synthetases and disease. Trends Mol. Med. 23,
693–708 (2017).
10. Scheper, G. C. et al. Mitochondrial aspartyl-tRNA synthetase deﬁciency causes
leukoencephalopathy with brain stem and spinal cord involvement and lactate
elevation. Nat. Genet. 39, 534–539 (2007).
11. Burrage, L. C. et al. Mitochondrial myopathy, lactic acidosis, and sideroblastic
anemia (MLASA) plus associated with a novel de novo mutation
(m.8969G>A) in the mitochondrial encoded ATP6 gene. Mol. Genet. Metab.
113, 207–212 (2014).
12. Torraco, A. et al. A novel mutation in NDUFB11 unveils a new clinical
phenotype associated with lactic acidosis and sideroblastic anemia. Clin.
Genet. 91, 441–447 (2017).
13. Wedatilake, Y. et al. TRNT1 deﬁciency: clinical, biochemical and molecular
genetic features. Orphanet J. Rare Dis. 11, 90 (2016).
14. Konovalova, S. & Tyynismaa, H. Mitochondrial aminoacyl-tRNA synthetases
in human disease. Mol. Genet Metab. 108, 206–211 (2013).
15. Hilander, T. et al. Editing activity for eliminating mischarged tRNAs is
essential in mammalian mitochondria. Nucleic Acids Res. 46, 849–860
(2018).
16. Nakamura, A., Yao, M., Chimnaronk, S., Sakai, N. & Tanaka, I. Ammonia
channel couples glutaminase with transamidase reactions in GatCAB. Science
312, 1954–1958 (2006).
17. Antonellis, A. & Green, E. D. The role of aminoacyl-tRNA synthetases in
genetic diseases. Annu Rev. Genom. Hum. Genet. 9, 87–107 (2008).
18. Boczonadi, V. & Horvath, R. Mitochondria: impaired mitochondrial
translation in human disease. Int J. Biochem Cell Biol. 48, 77–84 (2014).
19. Joshi-Tope, G. et al. Reactome: a knowledgebase of biological pathways.
Nucleic Acids Res. 33, D428–D432 (2005).
20. Rotig, A. Human diseases with impaired mitochondrial protein synthesis.
Biochim Biophys. Acta 1807, 1198–1205 (2011).
21. Fabregat, A. et al. The Reactome pathway Knowledgebase. Nucleic Acids Res.
44, D481–D487 (2016).
22. Thompson, K. et al. Recurrent de novo dominant mutations in SLC25A4
cause severe early-onset mitochondrial disease and loss of mitochondrial DNA
copy number. Am. J. Hum. Genet. 99, 860–876 (2016).
23. Simon, M. et al. Mutations of human NARS2, encoding the mitochondrial
asparaginyl-tRNA synthetase, cause nonsymdromic deafness and Leigh
syndrome. PLoS Genet. 11, e1005097 (2015).
24. Kopajtich, R. et al. Mutations in GTPBP3 cause a mitochondrial translation
defect associated with hypertrophic cardiomyopathy, lactic acidosis, and
encephalopathy. Am. J. Hum. Genet. 95, 708–720 (2014).
25. Oliveira, R. et al. Lethal neonatal LTBL associated with biallelec EARS2
variants: case report and review of the reported neuroradiological features.
JIMD Rep. 33, 61–68 (2017).
26. Hornig-Do, H. T. et al. Human mitochondrial leucyl tRNA synthetase can
suppress non cognate pathogenic mt-tRNA mutations. EMBO Mol. Med. 6,
183–193 (2014).
27. Sommerville, E. W. et al. Clinical FEatures, Molecular Heterogeneity, and
prognostic implications in YARS2-related mitochondrial myopathy. JAMA
Neurol. 74, 686–694 (2017).
28. Neveling, K. et al. A post-hoc comparison of the utility of sanger sequencing
and exome sequencing for the diagnosis of heterogeneous diseases. Hum.
Mutat. 34, 1721–1726 (2013).
29. Friederich, M. W. et al. Mutations in the accessory subunit NDUFB10 result in
isolated complex I deﬁciency and illustrate the critical role of intermembrane
space import for complex I holoenzyme assembly. Hum. Mol. Genet. 26,
702–716 (2017).
30. Kurolap, A. et al. Loss of glycine transporter 1 causes a subtype of glycine
encephalopathy with arthrogryposis and mildly elevated cerebrospinal ﬂuid
glycine. Am. J. Hum. Genet. 99, 1172–1180 (2016).
31. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic
Acids Res. 29, 308–311 (2001).
32. 1000 Genomes Project Consortium. et al. An integrated map of genetic
variation from 1,092 human genomes. Nature 491, 56–65 (2012).
33. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans.
Nature 536, 285–291 (2016).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06250-w
12 NATURE COMMUNICATIONS |  (2018) 9:4065 | DOI: 10.1038/s41467-018-06250-w |www.nature.com/naturecommunications
34. Scott, E. M. et al. Characterization of Greater Middle Eastern genetic variation
for enhanced disease gene discovery. Nat. Genet. 48, 1071–1076 (2016).
35. Genome of the Netherlands Consortium. Whole-genome sequence variation,
population structure and demographic history of the Dutch population. Nat.
Genet. 46, 818–825 (2014).
36. Adzhubei, I. A. et al. A method and server for predicting damaging missense
mutations. Nat. Methods 7, 248–249 (2010).
37. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat.
Protoc. 4, 1073–1081 (2009).
38. Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2:
mutation prediction for the deep-sequencing age. Nat. Methods 11, 361–362
(2014).
39. Rodenburg, R. J. Biochemical diagnosis of mitochondrial disorders. J. Inherit.
Metab. Dis. 34, 283–292 (2011).
40. Chatﬁeld, K. C. et al. Mitochondrial energy failure in HSD10 disease is due to
defective mtDNA transcript processing. Mitochondrion 21, 1–10 (2015).
41. Coughlin, C. R. 2nd et al. Mutations in the mitochondrial cysteinyl-tRNA
synthase gene, CARS2, lead to a severe epileptic encephalopathy and complex
movement disorder. J. Med. Genet. 52, 532–540 (2015).
42. Saada, A., Bar-Meir, M., Belaiche, C., Miller, C. & Elpeleg, O. Evaluation of
enzymatic assays and compounds affecting ATP production in mitochondrial
respiratory chain complex I deﬁciency. Anal. Biochem. 335, 66–72 (2004).
43. Smet, J. D., Devreese, B., Van Beeumen, J. & Van Coster, R. Nondenaturing
polyacrylaminde gel electrophoresis as a method for studying protein
interactions: applications in the analysis of mitochondrial OXPHOS
complexes. in Cell Biology: A Laboratory Handbook, Vol. 4, 259-264 (Elsevier,
Amsterdam, 2005).
44. Vanlander, A. V. et al. Two siblings with homozygous pathogenic splice-site
variant in mitochondrial asparaginyl-tRNA synthetase (NARS2). Hum. Mutat.
36, 222–231 (2015).
45. Wittig, I. et al. Assembly and oligomerization of human ATP synthase lacking
mitochondrial subunits a and A6L. Biochim Biophys. Acta 1797, 1004–1011
(2010).
46. Minczuk, M., Kolasinska-Zwierz, P., Murphy, M. P. & Papworth, M. A.
Construction and testing of engineered zinc-ﬁnger proteins for sequence-
speciﬁc modiﬁcation of mtDNA. Nat. Protoc. 5, 342–356 (2010).
47. Rorbach, J. et al. MRM2 and MRM3 are involved in biogenesis of the
large subunit of the mitochondrial ribosome. Mol. Biol. Cell. 25, 2542–2555
(2014).
48. Barufﬁni, E., Ferrero, I. & Foury, F. In vivo analysis of mtDNA replication
defects in yeast. Methods 51, 426–436 (2010).
49. Gietz, R. D. & Schiestl, R. H. High-efﬁciency yeast transformation using the
LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 31–34 (2007).
50. Bonneaud, N. et al. A family of low and high copy replicative, integrative
and single-stranded S. cerevisiae/E. coli shuttle vectors. Yeast 7, 609–615
(1991).
51. Merz, S. & Westermann, B. Genome-wide deletion mutant analysis reveals
genes required for respiratory growth, mitochondrial genome maintenance
and mitochondrial protein synthesis in Saccharomyces cerevisiae. Genome
Biol. 10, R95 (2009).
52. Mulero, J. J., Rosenthal, J. K. & Fox, T. D. PET112, a Saccharomyces cerevisiae
nuclear gene required to maintain rho+ mitochondrial DNA. Curr. Genet. 25,
299–304 (1994).
53. Wach, A., Brachat, A., Pohlmann, R. & Philippsen, P. New heterologous
modules for classical or PCR-based gene disruptions in Saccharomyces
cerevisiae. Yeast 10, 1793–1808 (1994).
54. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K. & Pease, L. R. Site-directed
mutagenesis by overlap extension using the polymerase chain reaction. Gene
77, 51–59 (1989).
55. The UniProt Consortium. UniProt: the universal protein knowledge base.
Nucleic Acids Res. 45, D158–D169 (2017).
56. Biasini, M. et al. SWISS-MODEL: modelling protein tertiary and quaternary
structure using evoluationary information. Nucleic Acids Res. 42, W252–W258
(2014).
57. Wu, J. et al. Insights into tRNA-dependent amidotransferase evoluation and
catalysis from the structure of the Aquifex aeolicus enzyme. J. Mol. Biol. 391,
703–716 (2009).
58. Nakamura, A. et al. Two distinct regions in Staphylococcus aureus
GatCAB guarantee accurate tRNA recognition. Nucleic Acids Res. 38, 672–682
(2010).
59. Araiso, Y. et al. Crystal structure of Saccharomyces cerevisiae mitochondrial
GatFAB reveals a novel subunit assembly in tRNA-dependent
amidotransferases. Nucleic Acids Res. 42, 6052–6063 (2014).
60. Schrödinger, LLC. The PyMOL Molecular Graphics System, Version 2.0,
accessed at https://pymol.org (2018).
61. Ito, T. & Yokoyama, S. Two enzymes bound to one transfer RNA assume
alternative conformations for consecutive reactions. Nature 467, 612–616
(2010).
Acknowledgements
We would like to thank the families for their participation in this study. We thank
the mitochondrial diagnostics group (muscle lab, cell culture lab, and DNA lab) of
the Radboud Center for Mitochondrial Medicine (RCMM) at the Translational Meta-
bolic Laboratory, Radboud UMC, as well as Carla Onnekink, Jeff Willemsen, Daisy
Dalloyaux, and Sander van de Groenendaal for excellent technical assistance. Mareike
Muhlmeister and Ulrich Brandt are thanked for performing mass spectrometry experi-
ments. We would like to acknowledge the Genome Technology Center at the Radboud
UMC and BGI Copenhagen for providing the exome sequencing service for patients
P1A and P1B. We like to thank the staff of the Colorado Fetal Care Center, the Children’s
Hospital Colorado fetal cardiology and neonatology programs and C. Freehauf, RN,
CGC for the expert clinical care of family 3. C.A.P., M.J.S., P.R.-G. and M.M. were
supported by the core funding from the Medical Research Council, UK
(MC_U105697135 and MC_UU_00015/4). J.V.H. and M.W.F. were supported by
Miracles for Mito, the Children’s Hospital Colorado Foundation and University of
Colorado Foundation. This work was supported by Telethon Foundation, Italy grant
GGP15041 to C.D. This work was also supported by Instituto de Salud Carlos III, http://
www.isciii.es/, PI13/00556 to R.G.; FEDER funds from the E.U. to R.G. and Instituto
de Salud Carlos III, http://www.isciii.es/, PI16/00789 to R.G. and M.A.F-M. P.R.-G.
was supported by Fundação para a Ciência e a Tecnologia (PD/BD/105750/2014).
Author contributions
M.W.F., S.T., C.A.P., S.P-Z., C.G., K.K., L.M., J.O., G.J.M.P., B.S. Jr., F.V.D.B, and L.T.W.
performed the in vitro experiments on patient ﬁbroblasts; C.Da. and M.G. performed the
yeast experiments; A.K., D.Br., T.G.J.D., K.B., K.C.C., T.C.F.-Z., R.C.G., C.H., R.K.H., H.
M., H.S., J.A.S., H.J.T.H., F.J.V.S., H.N.B., and J.L.K.V.H. performed patient clinical
evaluations, and gathered the phenotypic data; S.T., A.K., D.Bi., K.G., A.M., T.P., J.A.V.,
and E.W. participated in exome sequencing and bioinformatic data analysis; N.D-N., F.
F., A.F., L.K., performed Sanger sequencing and segregation analyses; M.K.D., E.W., M.
H.S., and Y.Z., performed pathology and electron microscopy analyses; C.A.P., C.Da., T.
G.J.D., K.B., I.F., R.G., D.L., M.H.S., M.J.S., H.J.T.H., F.J.V.S., J.A.V., M.A.F-M., H.N.B.,
C.Do., M.M., R.J.R., and J.L.K.V.H. participated in the conception, design, and data
analyses and interpretation of laboratory experiments; M.W.F., A.S. and L.T.W. per-
formed respiratory chain enzyme activity analysis in patient heart and skeletal muscle
samples; M.J.S. performed QARS localization experiments; P.R.-G. performed the
molecular modeling; M.W.F., S.T., C.Da., A.K., S.P-Z., T.G.J.D., K.B., C.G., L.M., T.P., B.
S. Jr., M.H.S., H.J.T.H., F.J.V.S., M.A.F.-M., H.N.B., C.Do., M.M., R.J.R., and J.L.K.V.H.
participated in writing, editing and critical review of the manuscript. All co-authors
reviewed and approved the ﬁnal version of the submitted manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-06250-w.
Competing interests: Dr. Smeitink is CEO of Khondrion, a mitochondrial medicine
company. This study did not pose a conﬂict of interest. All other authors declare no real
or apparent conﬂict of interest.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06250-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4065 | DOI: 10.1038/s41467-018-06250-w |www.nature.com/naturecommunications 13
Marisa W. Friederich1, Sharita Timal2,3, Christopher A. Powell4, Cristina Dallabona5, Alina Kurolap 6,7,
Sara Palacios-Zambrano8,9, Drago Bratkovic10, Terry G.J. Derks11, David Bick12, Katelijne Bouman13,
Kathryn C. Chatﬁeld14, Nadine Damouny-Naoum6,15, Megan K. Dishop16, Tzipora C. Falik-Zaccai17,18,
Fuad Fares15, Ayalla Fedida17,18, Ileana Ferrero5, Renata C. Gallagher1, Rafael Garesse8,9, Micol Gilberti5,
Cristina González8,9, Katherine Gowan19, Clair Habib20, Rebecca K. Halligan10, Limor Kalfon17, Kaz Knight1,
Dirk Lefeber21, Laura Mamblona8,9, Hanna Mandel7,17,22, Adi Mory6, John Ottoson1, Tamar Paperna6,
Ger J.M. Pruijn23, Pedro F. Rebelo-Guiomar4,24, Ann Saada25, Bruno Sainz Jr. 8,26, Hayley Salvemini10,
Mirthe H. Schoots27, Jan A. Smeitink 2, Maciej J. Szukszto 4, Hendrik J. ter Horst28, Frans van den Brandt2,
Francjan J. van Spronsen11, Joris A. Veltman21,29, Eric Wartchow16, Liesbeth T. Wintjes2, Yaniv Zohar30,
Miguel A. Fernández-Moreno8,9, Hagit N. Baris6,7, Claudia Donnini5, Michal Minczuk4,
Richard J. Rodenburg 2 & Johan L.K. Van Hove1
1Section of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado, Aurora 80045 CO, USA. 2Radboud Center for
Mitochondrial Medicine, Translational Metabolic Laboratory, Department of Pediatrics, Radboud University Medical Center, Nijmegen 6500 HB,
The Netherlands. 3Department of Human Genetics, Radboud Institute for Molecular Life Sciences and Donders Centre for Neuroscience, Radboud
University Medical Center, Nijmegen 6500 HB, The Netherlands. 4Medical Research Council, Mitochondrial Biology Unit, University of Cambridge,
Cambridge CB2 OXY, United Kingdom. 5Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma
43124, Italy. 6The Genetics Institute, Rambam Health Care Campus, Haifa 3109601, Israel. 7The Ruth and Bruce Rappaport Faculty of Medicine,
Technion – Israel Institute of Technology, Haifa 3109601, Israel. 8Departamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto
Sols” UAM-CSIC and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER). Facultad de Medicina, Universidad Autónoma
de Madrid, Madrid 28029, Spain. 9Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid 28041, Spain. 10SA Pathology,
Women and Children’s Hospital Adelaide, Adelaide 5006, Australia. 11Division of Metabolic Diseases, Beatrix Children’s Hospital, University
Medical Center Groningen, University of Groningen, Groningen 9700 RB, The Netherlands. 12HudsonAlpha Institute for Biotechnology, Huntsville,
AL 35806, USA. 13Department of Genetics, University Medical Center of Groningen, University of Groningen, Groningen 9700 RB, The Netherlands.
14Department of Pediatrics, Section of Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado, Aurora, CO 80045, USA.
15Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel. 16Department of Pathology, Children’s
Hospital Colorado, University of Colorado, Aurora 80045 CO, USA. 17Institute of Human Genetics, Galilee Medical Center, Nahariya 22100, Israel.
18The Azrieli Faculty of Medicine in the Galilee, Bar Ilan University, Safed 1311502, Israel. 19Department of Biochemistry and Molecular Genetics,
University of Colorado, Aurora, CO 80045, USA. 20Department of Pediatrics, Bnai Zion Medical Center, Haifa 3339419, Israel. 21Department of
Human Genetics, Radboud Institute for Molecular Life Sciences and Donders Centre for Neuroscience, Radboud University Medical Center,
Nijmegen 6500 HB, The Netherlands. 22Metabolic Unit, Rambam Health Care Campus, Haifa 3109601, Israel. 23Department of Biomolecular
Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen 6500 HB, The Netherlands. 24Graduate Program in Areas of Basic
and Applied Biology (GABBA), University of Porto, Porto 4200-135, Portugal. 25Monique and Jacques Roboh Department of Genetic Research and
the Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. 26Enfermedades
Crónicas y Cáncer Area, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain. 27Department of Pathology and Medical
Biology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. 28Division of Neonatology, Beatrix
Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, The Netherlands. 29Institute of Genetic
Medicine, Newcastle University, Newcastle NE1 3BZ, United Kingdom. 30Institute of Pathology, Rambam Health Care Campus, 3109601 Haifa,
Israel. These authors contributed equally: Marisa W. Friederich, Sharita Timal, Christopher A. Powell, Cristina Dallabona, Alina Kurolap, Sara
Palacios-Zambrano. These authors jointly supervised this work: Miguel A. Fernández-Moreno, Hagit N. Baris, Claudia Donnini, Michal Minczuk,
Richard J. Rodenburg, Johan L.K. Van Hove.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06250-w
14 NATURE COMMUNICATIONS |  (2018) 9:4065 | DOI: 10.1038/s41467-018-06250-w |www.nature.com/naturecommunications
